TQ Quiz | Pharmaceutical Update 2024 (Nashville 2024) by Events@optometricedu.com | Sep 26, 2024 | 2024 Nashville, TQ Courses | 0 comments "*" indicates required fields HiddenDate (Hidden) MM slash DD slash YYYY HiddenEvent Date (Hidden) MM slash DD slash YYYY HiddenEvent 60 days past date (Hidden) MM slash DD slash YYYY HiddenEvent Date Difference (Hidden)1. In the pharmaceutical resource matrix who is the best person for to discuss an “off-label” question or usage of the pharmaceutical:* A - Local sales representative B - Regional sales representative C - National sales representative D - Medical science liaison 2. The innate, adaptive, and complement systems are all parts of:* A - Digestive system B - Immune system C - Circulatory system D - Skeletal system 3. One of the best techniques or instruments to follow or management geographic atrophy is:* A - Ocular response analyzer (ORA) B - Cornea topography C - Fundus autofluorescence (FAF) D - OCT evaluation of the ganglion cell complex (GCC) and retina Nerve Fiber Layer (rNFL) 4. In February 2023 the FDA approved the first Treatment of geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD) this pharmaceutical is:* A - Syfovre (pegcetacoplan) B - Eylea (aflibercept) C - Vabysmo (faricimab-svoa) D - Xdemvy (lotilaner ophthalmic solution) 0.25% 5. Syfovre (pegcetacoplan) mechanism of action is regulating excessive activation of the complement cascade. Which part of the complement system is it inhibiting?* A - C1 B - C2 C - C3 D - C10 6. Izervay (avacincaptad pegol intravitreal solution) is FDA indicated for which ocular condition?* A - Keratoconus B - Vitreal floaters C - Glaucoma D - Geographic atrophy (AMD) 7. Izervay (avacincaptad pegol intravitreal solution) mechanism of action is regulating excessive activation of the complement cascade. Which part of the complement system is it inhibiting?* A - C1 B - C2 C - C5 D - C10 8. Eylea (aflibercept) as of January 2024 is indicated to treat ___ retinal conditions caused by ocular angiogenesis:* A - 1 B - 5 C - 10 D - 20 9. Which pharmaceutical has a mechanism of action that inhibits vascular endothelial growth factor (VEGF) and angiopoietin-2 (Ang-2) for the treatment of wet AMD or diabetic macular edema (DME)?* A - Xdemvy (lotilaner ophthalmic solution) 0.25% B - Miebo (perfluorohexyloctane ophthalmic solution) 100% C - Qlosi (pilocarpine hydrochloride ophthalmic solution) 0.4% D - Vabysmo (faricimab-svoa) 10. Which biologic drug is an injection and is used for the treatment of Neovascular (Wet) Age-related Macular Degeneration (AMD), it offers a 3-month dosing schedule in the first year of treat, but when used resulted in an adverse intraocular inflammation events?* A - Bevacizumab (Avastin) B - Ranibizumab (Lucentis) C - Aflibercept (Eylea) D - Brolucizumab-dbll (Beovu) 11. Which pharmaceutical was approved in July 2023 by the FDA to treat Demodex blepharitis?* A - Xdemvy (lotilaner ophthalmic solution) 0.25% B - Miebo (perfluorohexyloctane ophthalmic solution) 100% C - Qlosi (pilocarpine hydrochloride ophthalmic solution) 0.4% D - Iyuzeh (latanoprost ophthalmic solution) 0.005% 12. Which pharmaceutical works as an antiparasitic agent to target parasite-specific GABA-Chloride (Cl) channels* A - Miebo (perfluorohexyloctane ophthalmic solution) 100% B - Xdemvy (lotilaner ophthalmic solution) 0.25% C - Qlosi (pilocarpine hydrochloride ophthalmic solution) 0.4% D - Iyuzeh (latanoprost ophthalmic solution) 0.005% 13. Which pharmaceutical was approved in May 2023 by the FDA to treat the signs and symptoms of dry eye?* A - Xdemvy (lotilaner ophthalmic solution) 0.25% B - Miebo (perfluorohexyloctane ophthalmic solution) 100% C - Qlosi (pilocarpine hydrochloride ophthalmic solution) 0.4% D - Iyuzeh (latanoprost ophthalmic solution) 0.005% 14. Which pharmaceutical was approved in October 2023 by the FDA to treat the signs and symptoms of presbyopia?* A - Xdemvy (lotilaner ophthalmic solution) 0.25% B - Miebo (perfluorohexyloctane ophthalmic solution) 100% C - Qlosi (pilocarpine hydrochloride ophthalmic solution) 0.4% D - Iyuzeh (latanoprost ophthalmic solution) 0.005% 15. Which preservative free pharmaceutical was approved in December 2022 by the FDA for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension?* A - Xdemvy (lotilaner ophthalmic solution) 0.25% B - Miebo (perfluorohexyloctane ophthalmic solution) 100% C - Qlosi (pilocarpine hydrochloride ophthalmic solution) 0.4% D - Iyuzeh (latanoprost ophthalmic solution) 0.005% 16. Which pharmaceutical was approved in September 2023 by the FDA for the treatment of pharmacologically induced mydriasis (dilation reversal) produced by adrenergics?* A - Tropicamide 0.5% B - Tropicamide 1.0% C - Ryzumvi (phentolamine ophthalmic solution) 0.75% D - Mycombi (tropicamide and phenylephrine hydrochloride ophthalmic spray) 1% / 2.5% 17. Which of these glaucoma medications is considered a Rho kinase or ROCK NET inhibitor?* A - Timolol maleate B - Latanoprost C - Bimatoprost D - Netarsudil 18. Which biologic drug is indicated for the treatment of neurotrophic keratitis?* A - Teprotumumab-trbw (Tepezza) B - Cenegermin–bkbj (Oxervate) C - Tocilizumab (Actemra) D - Adalimumab (Humira) 19. Which of the following mechanisms most closely describes how cenegermin–bkbj (Oxervate) works?* A - It binds to IGF-1 receptor and blocks its activation and signaling B - It is a recombinant form of human nerve growth factor C - It blocks vascular endothelial growth factor D - It binds to TNF and blocks its action in the body 20. Which biologic drug is indicated for the treatment of non-infectious intermediate, posterior, and panuveitis in adults and children 2 years of age and older?* A - Teprotumumab-trbw (Tepezza) B - Cenegermin–bkbj (Oxervate) C - Tocilizumab (Actemra) D - Adalimumab (Humira) Personal InformationName* First Last Email* Phone*OE Tracker # License # Address* Street Address Address Line 2 City State / Province / Region ZIP / Postal Code AfghanistanAlbaniaAlgeriaAmerican SamoaAndorraAngolaAnguillaAntarcticaAntigua and BarbudaArgentinaArmeniaArubaAustraliaAustriaAzerbaijanBahamasBahrainBangladeshBarbadosBelarusBelgiumBelizeBeninBermudaBhutanBoliviaBonaire, Sint Eustatius and SabaBosnia and HerzegovinaBotswanaBouvet IslandBrazilBritish Indian Ocean TerritoryBrunei DarussalamBulgariaBurkina FasoBurundiCabo VerdeCambodiaCameroonCanadaCayman IslandsCentral African RepublicChadChileChinaChristmas IslandCocos IslandsColombiaComorosCongoCongo, Democratic Republic of theCook IslandsCosta RicaCroatiaCubaCuraçaoCyprusCzechiaCôte d'IvoireDenmarkDjiboutiDominicaDominican RepublicEcuadorEgyptEl SalvadorEquatorial GuineaEritreaEstoniaEswatiniEthiopiaFalkland IslandsFaroe IslandsFijiFinlandFranceFrench GuianaFrench PolynesiaFrench Southern TerritoriesGabonGambiaGeorgiaGermanyGhanaGibraltarGreeceGreenlandGrenadaGuadeloupeGuamGuatemalaGuernseyGuineaGuinea-BissauGuyanaHaitiHeard Island and McDonald IslandsHoly SeeHondurasHong KongHungaryIcelandIndiaIndonesiaIranIraqIrelandIsle of ManIsraelItalyJamaicaJapanJerseyJordanKazakhstanKenyaKiribatiKorea, Democratic People's Republic ofKorea, Republic ofKuwaitKyrgyzstanLao People's Democratic RepublicLatviaLebanonLesothoLiberiaLibyaLiechtensteinLithuaniaLuxembourgMacaoMadagascarMalawiMalaysiaMaldivesMaliMaltaMarshall IslandsMartiniqueMauritaniaMauritiusMayotteMexicoMicronesiaMoldovaMonacoMongoliaMontenegroMontserratMoroccoMozambiqueMyanmarNamibiaNauruNepalNetherlandsNew CaledoniaNew ZealandNicaraguaNigerNigeriaNiueNorfolk IslandNorth MacedoniaNorthern Mariana IslandsNorwayOmanPakistanPalauPalestine, State ofPanamaPapua New GuineaParaguayPeruPhilippinesPitcairnPolandPortugalPuerto RicoQatarRomaniaRussian FederationRwandaRéunionSaint BarthélemySaint Helena, Ascension and Tristan da CunhaSaint Kitts and NevisSaint LuciaSaint MartinSaint Pierre and MiquelonSaint Vincent and the GrenadinesSamoaSan MarinoSao Tome and PrincipeSaudi ArabiaSenegalSerbiaSeychellesSierra LeoneSingaporeSint MaartenSlovakiaSloveniaSolomon IslandsSomaliaSouth AfricaSouth Georgia and the South Sandwich IslandsSouth SudanSpainSri LankaSudanSurinameSvalbard and Jan MayenSwedenSwitzerlandSyria Arab RepublicTaiwanTajikistanTanzania, the United Republic ofThailandTimor-LesteTogoTokelauTongaTrinidad and TobagoTunisiaTurkmenistanTurks and Caicos IslandsTuvaluTürkiyeUS Minor Outlying IslandsUgandaUkraineUnited Arab EmiratesUnited KingdomUnited StatesUruguayUzbekistanVanuatuVenezuelaViet NamVirgin Islands, BritishVirgin Islands, U.S.Wallis and FutunaWestern SaharaYemenZambiaZimbabweÅland Islands Country Payment InformationPromotional Code Nashville 2024 - Pharmaceutical Update 2024 | TQ Credit*After 11/29/2024, pricing will increase to $30. Price: (Past 60 Days) Nashville 2024 - Pharmaceutical Update 2024E | TQ CreditThis course was presented over 60 days ago. Due to this late submission of TQ, your TQ credit price is $30. Price: Retake Discount Price: Promotional Discount Price: (Past 60 Days) Retake Discount Price: (Past 60 Days) Promotional Discount Price: Credit Card* HiddenCourse Information (HIDDEN)HiddenCourse Name (HIDDEN) HiddenRetake Code (HIDDEN) HiddenQuiz URL (HIDDEN)Do not include ending backslash (aka no .com/) HiddenCE Hours Submit a Comment Cancel replyYour email address will not be published. Required fields are marked *Comment * Name * Email * Website
